India’s Health Ministry Tightens Rules on Stem Cell Therapy

The Union Ministry of Health and Family Welfare rolled out a new advisory on Thursday, telling every state and Union territory to keep stem‑cell therapy strictly within the list of diseases that the centre has officially approved.

Why the sudden reminder? It stems from a Supreme Court judgment dated 30 January 2026 in the case of Yash Charitable Trust & Ors. v. Union of India & Ors. The court said that anyone offering stem‑cell treatments outside the approved roster is flouting the law and could face stiff penalties.

In plain language, doctors can now offer stem‑cell therapy as routine care only for the conditions the Ministry has earmarked. Anything else – whether it’s a fancy new protocol or a buzz‑worthy claim – is off‑limits unless it’s part of a duly sanctioned clinical trial.

One area that gets special mention is Autism Spectrum Disorder (ASD). The advisory makes it crystal clear that stem‑cell interventions for autism must remain confined to research trials that have cleared the National Guidelines for Stem Cell Research (2017), a joint effort of the Indian Council of Medical Research and the Department of Biotechnology. No commercial clinics, no “miracle cures” in the pipeline – just carefully monitored studies.

The ministry has asked state health departments, district regulators and both public and private hospitals to spread the Supreme Court’s directions far and wide. It also warned that ignoring the framework could trigger disciplinary action under Regulation 7.22 of the IMC Regulations 2002, or even lead to registration cancellation and penalties under Sections 32 and 40 of the Clinical Establishments (Registration and Regulation) Act 2010.

Backing the health ministry’s stance, the National Medical Commission (NMC) issued its own reminder on 5 September, reiterating that any unauthorised prescription, promotion or advertisement of stem‑cell therapy beyond the approved list will be treated as professional misconduct. The NMC has further asked state medical councils to investigate any alleged breaches and, where warranted, take action after due process.

In short, the message is simple: stem‑cell therapy is a promising tool, but in India it remains a tightly regulated medical service. If you hear a clinic promising a cure for something that isn’t on the approved list, chances are they’re overstepping the law.